Microbiological Characteristics and Clinical Outcomes, Including Mortality, Among Patients with Prosthetic Joint Infection: A Retrospective Study

Year 2026, Volume: 28 Issue: 1 , 40 - 46 , 25.04.2026

Semanur Kuzi , Nesibe Korkmaz , Bahar Çelik Arı , Sema Cihan , Evrim Duman , İrfan Şencan

https://doi.org/10.18678/dtfd.1759220

https://izlik.org/JA66AC78HZ

Abstract

Aim: Prosthetic joint infections (PJIs) are severe complications of joint arthroplasty, and their management has become increasingly complex in the era of antimicrobial resistance. This study aimed to evaluate the microbiological characteristics and clinical outcomes of PJIs in a high-resistance clinical setting. Material and Methods: This retrospective study included 74 patients diagnosed with PJI between January 2019 and June 2022 at a tertiary care hospital. Microbiological findings, antimicrobial resistance patterns, treatment outcomes, recurrence, and mortality were analyzed. Results: Microbiological growth was detected in 75.0% (n=54) of cases; 25.0% (n=18) were culture-negative. Among the 84 isolated pathogens, gram-negative bacteria accounted for 55.9% (n=47) and predominated particularly in early-onset infections. Staphylococcus aureus was the most frequently identified pathogen; however, carbapenem-resistant gram-negative organisms were common and were significantly associated with treatment failure (p=0.004) and mortality (p=0.011). Polymicrobial infections (35.2%, n=19) were independently associated with recurrence (p=0.001) and increased the odds of mortality (OR=7.91, 95% CI=1.42-52.61, p=0.017). Treatment success was significantly higher in patients with primary knee prostheses compared with hip or revision prostheses (p=0.029). Conclusion: PJIs in this study were characterized by a high burden of gram-negative and multidrug-resistant pathogens. Carbapenem resistance and polymicrobial etiology were key determinants of adverse outcomes, emphasizing the critical role of local antimicrobial resistance surveillance in guiding empirical treatment decisions.

Keywords

Prosthetic joint infection , antimicrobial resistance , gram-negative bacteria , carbapenem resistance , polymicrobial infection , treatment outcome

References

• Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89(4):780-5. doi:10.2106/JBJS.F.00222.
• Tekin-Taş Z, Özger HS, Kanatlı U, Hızel K. The incidence and risk factors of early periprosthetic joint infections. Infect Dis Clin Microbiol. 2024;6(2):93-101. doi:10.36519/idcm.2024.332.
• Singh JA, Yu S, Chen L, Cleveland JD. Rates of total joint replacement in the United States: future projections to 2020-2040 using the national inpatient sample. J Rheumatol. 2019;46(9):1134-40. doi:10.3899/jrheum.170990.
• Bedard NA, DeMik DE, Owens JM, Glass NA, DeBerg J, Callaghan JJ. Tobacco Use and risk of wound complications and periprosthetic joint infection: a systematic review and meta-analysis of primary total joint arthroplasty procedures. J Arthroplasty. 2019;34(2):385-96.e4. doi:10.1016/j.arth.2018.09.089.
• Premkumar A, Kolin DA, Farley KX, Wilson JM, McLawhorn AS, Cross MB, et al. Projected economic burden of periprosthetic joint infection of the hip and knee in the United States. J Arthroplasty. 2021;36(5):1484-9.e3. doi:10.1016/j.arth.2020.12.005.
• Lum ZC, Natsuhara KM, Shelton TJ, Giordani M, Pereira GC, Meehan JP. Mortality during total knee periprosthetic joint infection. J Arthroplasty. 2018;33(12):3783-8. doi:10.1016/j.arth.2018.08.021.
• Natsuhara KM, Shelton TJ, Meehan JP, Lum ZC. Mortality during total hip periprosthetic joint infection. J Arthroplasty. 2019; 34(7S):S337-42. doi:10.1016/j.arth.2018.12.024.
• Izakovicova P, Borens O, Trampuz A. Periprosthetic joint infection: current concepts and outlook. EFORT Open Rev. 2019;4(7):482-94. doi:10.1302/2058-5241.4.180092.
• Schwarz EM, Parvizi J, Gehrke T, Aiyer A, Battenberg A, Brown SA, et al. 2018 International Consensus Meeting on Musculoskeletal Infection: research priorities from the general assembly questions. J Orthop Res. 2019;37(5):997-1006. doi:10.1002/jor.24293.
• Sandiford NA, Francescini M, Kendoff D. The burden of prosthetic joint infection (PJI). Ann Joint. 2021;6:25. doi:10.21037/aoj-2020-pji-11.
• Aslan L, Gedik CC, Karaismailoğlu B, Özşahin MK, Kaynak G, Öztürk R, et al. Early periprosthetic joint infection rates following total hip and knee arthroplasty: a single-center study. Cerrahpaşa Med J. 2023;47(3):264-9. doi:10.5152/cjm.2023.23054.
• Stevoska S, Himmelbauer F, Stiftinger J, Stadler C, Pisecky L, Gotterbarm T, et al. Significant difference in antimicrobial resistance of bacteria in septic revision between total knee arthroplasty and total hip arthroplasty. Antibiotics (Basel). 2022;11(2):249. doi:10.3390/antibiotics11020249.
• Drago L, De Vecchi E, Bortolin M, Zagra L, Romanò CL, Cappelletti L. Epidemiology and antibiotic resistance of late prosthetic knee and hip infections. J Arthroplasty. 2017;32(8):2496-500. doi:10.1016/j.arth.2017.03.005.
• Benito N, Franco M, Ribera A, Soriano A, Rodriguez-Pardo D, Sorlí L, et al. Time trends in the aetiology of prosthetic joint infections: a multicentre cohort study. Clin Microbiol Infect. 2016;22(8):732.e1-8. doi:10.1016/j.cmi.2016.05.004.
• Tande AJ, Patel R. Prosthetic joint infection. Clin Microbiol Rev. 2014;27(2):302-45. doi:10.1128/CMR.00111-13.
• Benito N, Mur I, Ribera A, Soriano A, Rodríguez-Pardo D, Sorlí L, et al. The different microbial etiology of prosthetic joint infections according to route of acquisition and time after prosthesis implantation, including the role of multidrug-resistant organisms. J Clin Med. 2019;8(5):673. doi:10.3390/jcm8050673.
• Dedeogullari ES, Slullitel P, Horton I, Atilla B, Salih S, Monk P, et al. Comparison of microbiological profiles of primary hip and knee peri-prosthetic joint infections treated at specialist centers around the world. Microorganisms. 2025;13(7):1505. doi:10.3390/microorganisms13071505.
• Stammers J, Kahane S, Ranawat V, Miles J, Pollock R, Carrington RW, et al. Outcomes of infected revision knee arthroplasty managed by two-stage revision in a tertiary referral centre. Knee. 2015;22(1):56-62. doi:10.1016/j.knee.2014.10.005.
• Hu L, Fu J, Zhou Y, Chai W, Zhang G, Hao L, et al. Trends in microbiological profiles and antibiotic resistance in periprosthetic joint infections. J Int Med Res. 2021;49(3):3000605211002784. doi:10.1177/03000605211002784.
• Vasso M, Schiavone Panni A, De Martino I, Gasparini G. Prosthetic knee infection by resistant bacteria: the worst-case scenario. Knee Surg Sports Traumatol Arthrosc. 2016;24(10):3140-6. doi:10.1007/s00167-016-4010-8.
• Frost I, Van Boeckel TP, Pires J, Craig J, Laxminarayan R. Global geographic trends in antimicrobial resistance: the role of international travel. J Travel Med. 2019;26(8):taz036. doi:10.1093/jtm/taz036.
• Holleyman RJ, Baker P, Charlett A, Gould K, Deehan DJ. Microorganisms responsible for periprosthetic knee infections in England and Wales. Knee Surg Sports Traumatol Arthrosc. 2016;24(10):3080-7. doi:10.1007/s00167-015-3539-2.
• Tan TL, Kheir MM, Tan DD, Parvizi J. Polymicrobial periprosthetic joint infections: outcome of treatment and identification of risk factors. J Bone Joint Surg Am. 2016;98(24):2082-8. doi:10.2106/JBJS.15.01450.
• Preobrazhensky P, Bozhkova S, Kochish A, Tikhilov R, Kazemirsky A. Comparative analysis of pathogen structure in patients with PJI after primary total hip and knee arthroplasty. Arch Orthop Trauma Surg. 2021;141(11):1963-9. doi:10.1007/s00402-021-04139-w.